{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(3)"],"submitter":["Yeku OO"],"pubmed_abstract":["<h4>Background</h4>Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC.<h4>Methods</h4>PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3 mg/kg o"],"journal":["Journal for immunotherapy of cancer"],"pagination":["e010959"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11907075"],"repository":["biostudies-literature"],"pubmed_title":["Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer."],"pmcid":["PMC11907075"],"pubmed_authors":["Kyriakopoulos C","Lynam SK","Gordon M","Hubbard J","Fu S","Chamberlain M","Richardson DL","Wang J","Naqash AR","Barve M","Kummar S","Yeku OO","Dowlati A","LoRusso P","Winer I","Patnaik A","Tan WW"],"additional_accession":[]},"is_claimable":false,"name":"Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.","description":"<h4>Background</h4>Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC.<h4>Methods</h4>PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3 mg/kg o","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-04-26T05:49:19.034Z","creation":"2025-04-06T11:38:46.271Z"},"accession":"S-EPMC11907075","cross_references":{"pubmed":["40081941"],"doi":["10.1136/jitc-2024-010959"]}}